Alpha-Lipoic Acid: Why "600 mg" Is Really 300 mg of Active R
Educational overview — not medical advice. ALA can lower blood sugar; if you take insulin or a sulfonylurea, or have a thyroid/autoimmune history, see does it work for the safety cautions.
Alpha-lipoic acid comes in two mirror-image forms — and only the R-(+) one is the active, body-made form. Most products are racemic (50/50 R/S), so a labeled "600 mg" cap = ~300 mg active R. The obvious move is "buy R-ALA instead" — but the data says the opposite on value: priced per mg of actual active R, bulk racemic is the cheapest source of R ($0.03/100 mg R), while premium R-ALA / stabilized sodium-R-lipoate costs ~6× more per mg of R. R-ALA's genuine edge is absorption, not cost (Carlson 2007). The evidence is real but specific: diabetic neuropathy (IV > oral), a split glycemic signal, a small weight effect.
As an Amazon Associate we earn from qualifying purchases. Ranked by cost per 100 mg of active R-ALA, never commissions.
Start here
What alpha-lipoic acid is (and what "active" means here)
ALA is a sulfur-containing compound your body makes in small amounts and uses as an antioxidant and a cofactor in mitochondrial energy metabolism. The supplement wrinkle is chirality: ALA exists as two non-superimposable mirror-image forms, R-(+) and S-(−), and only the R-(+) enantiomer is the one the body synthesizes and the biologically active form (Salehi 2019). Manufacturing plain ALA yields a racemic 50/50 mix, so the first thing to know about any "alpha-lipoic acid" bottle is that half of a racemic dose is the inactive S form — a labeled 600 mg supplies about 300 mg of active R.
The moat, honestly: R is active, but racemic is the cheaper source of it
Here's where most write-ups go wrong. Because only R is active, the naive advice is "skip racemic, buy R-ALA." But when you compute cost per mg of the actual active R across products, the ranking flips: bulk racemic is the cheapest source of active R, because it's manufactured at scale and sold in large counts, so even paying for the "wasted" S half, its active-R cost is the lowest of the field. Premium R-ALA and stabilized sodium-R-lipoate (Na-R-ALA) cost roughly 6× more per mg of R. So R-ALA's real advantage isn't "more active per dollar" — it's absorption: stabilized sodium-R-lipoate reaches higher peak plasma levels (Cmax/AUC) than plain racemic ALA in human pharmacokinetic testing (Carlson 2007 — a small, non-MEDLINE-journal study; we cite it for absorption only). See R vs racemic for the full breakdown, including the "R-ALA Complex" label that sounds like R-ALA but is mostly racemic.
The one-line takeaway Only R-(+)-lipoic acid is active, so a racemic "600 mg" is ~300 mg of active R — but priced per mg of that active R, bulk racemic is the cheapest source ($0.03/100 mg R), and R-ALA/Na-R-ALA cost more per mg of R. You're buying absorption with R-ALA, not more active. Of the 13 products we track, 8 are racemic, 4 are genuine R-form, and 1 is a mostly-racemic "R" blend.
Does it work? (the short version)
Modestly and specifically. Diabetic neuropathy: the strongest result is intravenous — 600 mg/day IV for 3 weeks improved symptoms ~24% (Ziegler 2004); oral is favorable and dose-related (Hsieh 2023), but a 2024 Cochrane review found oral ALA over ≥6 months has little or no durable effect (Baicus 2024) — so IV > oral. Blood sugar: positive across metabolic-disease populations (Akbari 2018) but null in uncomplicated type 2 diabetes (Ebada 2019) — not a glucose-drug substitute. Weight: small, ~−0.69 kg (Namazi 2018). And there are real safety landmines — additive hypoglycemia with antidiabetic drugs, and reported insulin-autoimmune (Hirata) cases — on the evidence page.
Frequently asked questions
What is alpha-lipoic acid?
A body-made antioxidant and energy-metabolism cofactor. It has two mirror-image forms; only R-(+) is active. Most products are racemic (50/50 R/S), so a "600 mg" cap = ~300 mg active R. Standard studied dose 600 mg/day.
Is R-ALA better than racemic?
Not for value. Priced per mg of active R, bulk racemic is the cheapest source (~$0.03/100 mg R); R-ALA costs ~6× more per mg of R. R-ALA's edge is absorption (Carlson 2007), not more active per dollar.
Does it work?
Specifically. Neuropathy: IV strong (Ziegler 2004), oral weaker and null long-term (Baicus 2024 Cochrane). Glycemic split: positive in metabolic disease (Akbari 2018), null in uncomplicated T2D (Ebada 2019). Weight small (Namazi 2018).
How much should I take?
600 mg/day is the standard studied oral dose (range 300–1,800; trials used racemic). 600 mg racemic = ~300 mg active R. Cautions: additive hypoglycemia with insulin/sulfonylureas; reported insulin-autoimmune cases at ~600 mg/day.
Related guides
- Milk thistle — another "the active isn't the big number on the label" category (silymarin)
- Berberine — the other popular metabolic/glycemic supplement, with its own bioavailability problem
- NAC — a related sulfur-antioxidant with a genuinely different evidence base
Sources
- Salehi B, et al. "Insights on the Use of α-Lipoic Acid for Therapeutic Purposes." Biomolecules. 2019. PMID: 31405030 (R-(+) is the natural, active enantiomer; commercial ALA is widely racemic; R shows better bioavailability than S).
- Carlson DA, et al. "The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects." Altern Med Rev. 2007. PMID: 18069903 (higher Cmax/AUC for stabilized sodium-R-lipoate; small human PK study, n=12; non-MEDLINE journal — cited for absorption only).
- Ziegler D, et al. "Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid (SYDNEY 2)." Diabet Med. 2004. PMID: 14984445 (IV 600 mg/day, TSS improved ~24.1%).
- Baicus C, et al. "Alpha-lipoic acid for diabetic peripheral neuropathy." Cochrane Database Syst Rev. 2024. PMID: 38205823 (oral ≥6 months: little or no effect).
- Full product dataset: /alpha-lipoic-acid/cost-by-brand.json (CC BY 4.0).